Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDY -1.87%74 Owner Earnings per Share (TTM) is 1.72 as of Dec. 2025, which is 80% below its 10-year median of 8.43. GuruFocus rates SHTDY with a GF Score™ of 74/100 and a GF Value™ of $13.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 65 Medical Distribution companies, Sinopharm Group Co ranks better than 76.92% on this metric.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Sinopharm Group Co's Owner Earnings per Share (TTM) ended in Dec. 2025 was $1.72. It's Price-to-Owner-Earnings ratio for today is 6.41.
The historical rank and industry rank for Sinopharm Group Co's Owner Earnings per Share (TTM) or its related term are showing as below:
SHTDY'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.92 Med: 8.43 Max: 85.65
Current: 6.41
SHTDY's Price-to-Owner-Earnings is ranked better than 76.92% of 65
companies
in the Medical Distribution industry
Industry Median: 11.81
vs SHTDY: 6.41
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Sinopharm Group Co Owner Earnings per Share (TTM) Related Terms
Sinopharm Group Co Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Owner Earnings per Share (TTM) Chart
SHTDY vs MCK, CAH, COR: Owner Earnings per Share (TTM) Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Price-to-Owner-Earnings vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
1. Start with "Net Income" from income statement. Sinopharm Group Co's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was $1,016 Mil.
3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income.
Sinopharm Group Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was $0 Mil.
4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $171 Mil
It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.
The following shows how to get maintenance capital expenditure.
First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.
Sinopharm Group Co's 5-Year Average Maintenance Capital Expenditure = $171 Mil
5. "Change In Working Capital" is from cashflow statement. Sinopharm Group Co's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was $-391 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Owner Earnings per Share (TTM) of 1.72 mean?
Sinopharm Group Co (SHTDY) has a Owner Earnings per Share (TTM) of 1.72 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Sinopharm Group Co. This is 80% below median its historical median of 8.43. Over the past decade, Sinopharm Group Co's Owner Earnings per Share (TTM) has ranged from 4.92 to 85.65. According to the industry distribution chart, Sinopharm Group Co ranks #15 out of 65 companies in the Medical Distribution industry, placing it in the top 23.1%.
Is Sinopharm Group Co's Owner Earnings per Share (TTM) too high?
Sinopharm Group Co's current Owner Earnings per Share (TTM) of 1.72 is 80% below median its 10-year median of 8.43. Over the past 10 years, this metric has ranged from a low of 4.92 to a high of 85.65. The Medical Distribution industry median Owner Earnings per Share (TTM) is 11.81. Sinopharm Group Co's value of 1.72 is 85.4% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #15 out of 65 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Owner Earnings per Share (TTM) compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #15 out of 65 companies for Owner Earnings per Share (TTM). This places Sinopharm Group Co in the top 23% of its industry — outperforming the majority of peers. The industry median Owner Earnings per Share (TTM) is 11.81. Sinopharm Group Co's value of 1.72 is 85.4% below this benchmark. Historically, Sinopharm Group Co's own Owner Earnings per Share (TTM) has ranged from 4.92 to 85.65 over the past decade. While the company's 10-year median is 8.43 vs. the industry median of 11.81, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Medical Distribution company?
The median Owner Earnings per Share (TTM) among Medical Distribution companies is 11.81, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Owner Earnings per Share (TTM) of 1.72 is 85.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Sinopharm Group Co. For the Medical Distribution industry, the median Owner Earnings per Share (TTM) is 11.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Owner Earnings per Share (TTM) is 1.72, which is 80% below median its own 10-year median of 8.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.60, compared to a current price of $11.03 — trading 18.9% below its estimated fair value. The current Owner Earnings per Share (TTM) is 1.72, which is 80% below median its 10-year median of 8.43 and 85.4% below the Medical Distribution industry median of 11.81. Sinopharm Group Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Owner Earnings per Share (TTM) is 1.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $11.03 is trading 18.9% below its estimated GF Value™ of $13.60.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Owner Earnings per Share (TTM): 1.72 (80% below median its 10-year median of 8.43)
GF Value™: $13.60 vs. price of $11.03 (18.9% below fair value)
Industry Position: 85.4% below the Medical Distribution median (#15 of 65)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
74GF Score
Get the complete analysis for SHTDY
Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
